Education
About Us
Working with TipRanks
Follow Us
Tryptamine Therapeutics Limited (AU:ENP)
ASX:ENP
Total Valuation
Tryptamine Therapeutics has a market cap or net worth of AU$49.89M. The enterprise value is AU$0.00.
Market CapAU$49.89M
Enterprise ValueAU$0.00
Share Statistics
Tryptamine Therapeutics has 1,609,510,100 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,609,510,100
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Tryptamine Therapeutics’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee0.00
Profits Per Employee-106.65K
Employee Count50
Asset Turnover―
Inventory Turnover―
Valuation Ratios
The current PE Ratio of Tryptamine Therapeutics is ―. Tryptamine Therapeutics’s PEG ratio is 0.00.
PE Ratio―
PS Ratio0.00
PB Ratio0.00
Price to Fair Value―
Price to FCF0.00
Price to Operating Cash Flow―
PEG Ratio0.00
Income Statement
In the last 12 months, Tryptamine Therapeutics had revenue of 0.00 and earned -5.33M in profits. Earnings per share was 0.00.
Revenue0.00
Gross Profit-54.34K
Operating Income-6.73M
Pretax Income-6.91M
Net Income-5.33M
EBITDA-5.27M
Earnings Per Share (EPS)0.00
Cash Flow
In the last 12 months, operating cash flow was -7.77M and capital expenditures -129.28K, giving a free cash flow of -7.90M billion.
Operating Cash Flow-7.77M
Free Cash Flow-7.90M
Free Cash Flow per Share>-0.01
Dividends & Yields
Tryptamine Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.86
52-Week Price Change―
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)1.64M
Important Dates
Tryptamine Therapeutics upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Tryptamine Therapeutics as a current ratio of ―, with Debt / Equity ratio of ―
Current Ratio―
Quick Ratio―
Debt to Market Cap―
Net Debt to EBITDA―
Interest Coverage Ratio―
Taxes
In the past 12 months, Tryptamine Therapeutics has paid -1.58M in taxes.
Income Tax-1.58M
Effective Tax Rate―
Enterprise Valuation
Tryptamine Therapeutics EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
Tryptamine Therapeutics has AU$3.03M in cash and marketable securities with AU$0.00 in debt, giving a net cash position of AU$3.03M billion.
Cash & Marketable SecuritiesAU$3.03M
Total DebtAU$0.00
Net CashAU$3.03M
Net Cash Per Share<AU$0.01
Tangible Book Value Per Share―
Margins
Gross margin is ―, with operating margin of ―, and net profit margin of ―.
Gross Margin―
Operating Margin―
Pretax Margin―
Net Profit Margin―
EBITDA Margin―
EBIT Margin―
Analyst Forecast
The average price target for Tryptamine Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―